Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

28 February 2011 Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority

CSL Behring announces a special edition of its Key Issues Dialogue series released in conjunction with Rare Disease Day 2011, an international event to raise awareness of rare diseases and their impact on people’s lives. The Dialogue spanned two continents and provided a platform for sharing and exploring important information and ideas for patients, caregivers and healthcare providers.

> Read More
24 February 2011 CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra® to 30 Months

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, from 24 months to 30 months. Hizentra, the first and only 20 percent subcutaneous immunoglobulin (SCIg) approved in the U.S., is the only SCIg in the U.S. that can be stored at room temperature throughout its entire shelf life.

> Read More
18 February 2011 CSL Behring Receives FDA Approval of Corifact™ for Treatment of Congenital Factor XIII Deficiency

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.

> Read More
20 January 2011 CSL Behring Awards Advocacy Grants To Patient Groups In Maryland, New England, The Midwest And Washington

CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded advocacy grants totaling almost $100,000 to six patient organizations through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations committed to helping people who use plasma-derived or recombinant therapies to manage rare and serious diseases.

> Read More
06 December 2010 CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti

Direct Relief International announced today that CSL Behring has donated critically needed medical supplies to assist cholera patients in Haiti. The products will be used at Justinian University Hospital (JUH) in Cap-Haitien. JUH is the main public hospital for the entire northern sector of the country; the I.V. solutions and supplies will also be distributed to the numerous cholera treatment units (CTUs) that have been established in the cholera outbreak area as dictated by need.

> Read More
Page 26 of 50 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+